| Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC (NCT04530708) | Swedish Lung Cancer Study Group | 2017-02-01 |
| Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (NCT02998567) | Royal Marsden NHS Foundation Trust | 2017-01-26 |
| 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer (NCT03065764) | Amsterdam UMC, location VUmc | 2017-01-20 |
| Pembrolizumab in Elderly Patients With Advanced Lung Cancer (NCT03293680) | Spanish Lung Cancer Group | 2017-01-15 |
| A Prospective, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracoscopic Lobectomies (NCT03056300) | Ethicon, Inc. | 2017-01-11 |
| PET/CT-directed Hyperfractionated Radiation Dose Escalation in Stage III Non-small Cell Lung Cancer (NCT03099577) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2017-01-02 |
| FDG PET/CT Radiomics Analyses of Lung Cancer Patients Treated With Immunotherapy (NCT04007068) | Institute of Oncology Ljubljana | 2017-01-01 |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients (NCT02661100) | Case Comprehensive Cancer Center | 2017-01-01 |
| Effect of Preoperative Oral Carbohydrate Administration in Thoracic Surgery Patients (NCT05005091) | Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital | 2017-01-01 |
| Subcostal Single-port Versus Intercostal Multi-port Robotic Lobectomy for Non-small Cell Lung Cancer (NCT07099105) | Korea University Guro Hospital | 2017-01-01 |
| Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients (NCT02914990) | Betta Pharmaceuticals Co., Ltd. | 2016-12-29 |
| Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT02944396) | AbbVie | 2016-12-23 |
| A Study of the Correlation Between CRF, Survival and Physiological Factors in NSCLC Patients Under Chemotherapy (NCT03130192) | Chung Shan Medical University | 2016-12-22 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (NCT02983045) | Nektar Therapeutics | 2016-12-19 |
| Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (NCT02183883) | University College, London | 2016-12-16 |
| Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (NCT03086733) | University Health Network, Toronto | 2016-12-05 |
| Food Reward in Cachexia Induced by Acute or Chronic Disease (NCT02798003) | Maastricht University Medical Center | 2016-12-01 |
| Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC (NCT03374280) | Guangzhou Medical University | 2016-12-01 |
| Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLC (NCT04710459) | Mohamed Abdel Bary Ahmed Ibrahim | 2016-12-01 |
| Hyperpolarized Noble Gas MRI Detection of Radiation-Induced Lung Injury (NCT03632369) | Thunder Bay Regional Health Research Institute | 2016-12-01 |
| Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (NCT06207292) | Radiotherapy Oncology Centre "Santa Maria" Hospital | 2016-12-01 |
| An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (NCT03129256) | Changzhou Cancer Hospital of Soochow University | 2016-12-01 |
| Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) (NCT03060343) | Yu Fenglei | 2016-11-28 |
| Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer (NCT03299478) | University Hospital of North Norway | 2016-11-28 |
| A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer (NCT02779751) | Eli Lilly and Company | 2016-11-14 |
| Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC. (NCT03130881) | Beijing Pearl Biotechnology Limited Liability Company | 2016-11-08 |
| Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative (NCT03758287) | Sunshine Lake Pharma Co., Ltd. | 2016-11-01 |
| Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation (NCT02961270) | Chinese Academy of Medical Sciences | 2016-11-01 |
| Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients (NCT02965391) | Peking University People's Hospital | 2016-11-01 |
| Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (NCT02835599) | AstraZeneca | 2016-11-01 |
| 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study (NCT02938546) | Shanghai Chest Hospital | 2016-11-01 |
| Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance (NCT02930954) | Caicun Zhou | 2016-11-01 |
| Pembrolizumab-PET Imaging (NCT02760225) | University Medical Center Groningen | 2016-10-24 |
| A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer (NCT02789345) | Eli Lilly and Company | 2016-10-24 |
| Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC (NCT02768558) | RTOG Foundation, Inc. | 2016-10-17 |
| Efficacy Study of Comprehensive Rehabilitation Program in Postoperative NSCLC Patients (NCT03244605) | Shanghai University of Traditional Chinese Medicine | 2016-10-01 |
| Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients (NCT02579564) | Xinqiao Hospital of Chongqing | 2016-10-01 |
| Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients (NCT03372694) | Shanghai University of Traditional Chinese Medicine | 2016-10-01 |
| Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer (NCT02570815) | St. Joseph's Healthcare Hamilton | 2016-10-01 |
| The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. (NCT03384511) | Shandong Cancer Hospital and Institute | 2016-09-30 |
| KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy) (NCT02777567) | AstraZeneca | 2016-09-29 |
| A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NCT02848651) | Genentech, Inc. | 2016-09-23 |
| Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel (NCT02684461) | UNC Lineberger Comprehensive Cancer Center | 2016-09-13 |
| MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors (NCT02669914) | Washington University School of Medicine | 2016-09-12 |
| Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M (NCT02841579) | MedSIR | 2016-09-02 |
| Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type (NCT02906150) | SciClone Pharmaceuticals | 2016-09-01 |
| Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program (NCT02933346) | Intergroupe Francophone de Cancerologie Thoracique | 2016-09-01 |
| Prognostic PET/CT Model in Non Small Cell Lung Cancer (NCT03199599) | Poitiers University Hospital | 2016-09-01 |
| Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study (NCT02907606) | Peking University People's Hospital | 2016-09-01 |
| DE-CT in Lung Cancer Proton Therapy (NCT02844140) | Maastricht Radiation Oncology | 2016-09-01 |
| Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer (NCT02635061) | Celgene | 2016-08-25 |
| Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer (NCT02417662) | University College, London | 2016-08-19 |
| Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer (NCT02718066) | HUYABIO International, LLC. | 2016-08-18 |
| Improving Pulmonary Function Following Radiation Therapy (NCT02843568) | University of Wisconsin, Madison | 2016-08-17 |
| A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (NCT02860780) | Eli Lilly and Company | 2016-08-10 |
| INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer (NCT02764086) | Cancer Trials Ireland | 2016-08-10 |
| Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy (NCT02910999) | Bristol-Myers Squibb | 2016-08-09 |
| Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) (NCT02835690) | Merck Sharp & Dohme LLC | 2016-08-04 |
| Analysis of Soluble Mediators,Cytokines and FACs as Prognostic Factors in Advanced Non-squamous Lung Carcinoma (NCT03156868) | Spanish Lung Cancer Group | 2016-08-03 |
| Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC (NCT02771314) | Hellenic Oncology Research Group | 2016-08-02 |
| Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing (NCT02906852) | Inivata | 2016-08-01 |
| Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer (NCT02731001) | Technische Universität Dresden | 2016-08-01 |
| Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study (NCT03850444) | Merck Sharp & Dohme LLC | 2016-08-01 |
| An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study (NCT02884479) | SciClone Pharmaceuticals International (Cayman) Development Limited | 2016-08-01 |
| EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism (NCT02859077) | Shanghai Pulmonary Hospital, Shanghai, China | 2016-08-01 |
| Energy for Lymphocytes (NCT04879316) | Hôpital Cochin | 2016-08-01 |
| Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer (NCT04977791) | Shanghai Chest Hospital | 2016-07-21 |
| Parametric Imaging in Positron Emission Tomography for Patient With Lung Cancer (NCT02821936) | Centre Henri Becquerel | 2016-07-13 |
| A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NCT02754882) | Samsung Bioepis Co., Ltd. | 2016-07-05 |
| Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow (NCT03551951) | University of Missouri-Columbia | 2016-07-01 |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) (NCT02576665) | Tocagen Inc. | 2016-07-01 |
| Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer (NCT02991924) | National Cancer Center, Korea | 2016-07-01 |
| Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer. (NCT02968979) | Chugai Pharma France | 2016-07-01 |
| A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors (NCT02886897) | Sun Yat-sen University | 2016-07-01 |
| Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) (NCT02419170) | Washington University School of Medicine | 2016-07-01 |
| Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers (NCT02838836) | University of Missouri-Columbia | 2016-07-01 |
| CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor (NCT02839954) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-07-01 |
| Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS) (NCT02679170) | Pfizer | 2016-06-29 |
| Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers (NCT02803203) | Memorial Sloan Kettering Cancer Center | 2016-06-29 |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) (NCT02775435) | Merck Sharp & Dohme LLC | 2016-06-09 |
| Acquired Resistant Mechanism of the First-generation EGFR TKIs (NCT02804217) | Zhejiang Cancer Hospital | 2016-06-01 |
| Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer (NCT02770014) | Dana-Farber Cancer Institute | 2016-06-01 |
| eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (NCT02767804) | Xcovery Holdings, Inc. | 2016-06-01 |
| First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation (NCT02883543) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2016-06-01 |
| A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus (NCT02752126) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2016-06-01 |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (NCT02737501) | Ariad Pharmaceuticals | 2016-05-26 |
| Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK (NCT02658747) | Hoffmann-La Roche | 2016-05-25 |
| Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (NCT02609776) | Janssen Research & Development, LLC | 2016-05-24 |
| GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients (NCT02575404) | Providence Health & Services | 2016-05-16 |
| Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer (NCT03746262) | Wake Forest University Health Sciences | 2016-05-13 |
| Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy (NCT03042221) | University of Colorado, Denver | 2016-05-10 |
| Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (NCT02716311) | Intergroupe Francophone de Cancerologie Thoracique | 2016-05-01 |
| Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer (NCT02780778) | Tianjin Medical University Cancer Institute and Hospital | 2016-05-01 |
| Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy (NCT02788461) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2016-05-01 |
| Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) (NCT02681549) | Yale University | 2016-05-01 |
| Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) (NCT02705339) | Washington University School of Medicine | 2016-05-01 |
| A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) (NCT02657434) | Hoffmann-La Roche | 2016-04-30 |
| Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer (NCT02713529) | AmMax Bio, Inc. | 2016-04-14 |
| An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (NCT02658890) | Bristol-Myers Squibb | 2016-04-14 |
| Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols (NCT02682667) | National Cancer Institute (NCI) | 2016-04-11 |